ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,699.98
-0.30%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) News

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACRV
DateTimeSourceHeadlineSymbolCompany
24/04/202421:01GlobeNewswire Inc.Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventNASDAQ:ACRVAcrivon Therapeutics Inc
17/04/202401:01GlobeNewswire Inc.Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
10/04/202413:00GlobeNewswire Inc.Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable ResistancNASDAQ:ACRVAcrivon Therapeutics Inc
09/04/202412:00GlobeNewswire Inc.Acrivon Therapeutics Announces $130 Million Private Placement FinancingNASDAQ:ACRVAcrivon Therapeutics Inc
28/03/202412:00GlobeNewswire Inc.Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
06/03/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
06/03/202421:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
05/03/202421:30GlobeNewswire Inc.Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
04/03/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
04/03/202413:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
27/02/202413:00GlobeNewswire Inc.Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/02/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/02/202420:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRVAcrivon Therapeutics Inc
08/02/202413:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
08/02/202413:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
06/02/202413:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
19/01/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
12/01/202421:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
08/01/202412:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
04/01/202413:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
18/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRVAcrivon Therapeutics Inc
08/12/202321:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
01/12/202321:35Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRVAcrivon Therapeutics Inc
28/11/202313:58Dow Jones NewsAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer AssayNASDAQ:ACRVAcrivon Therapeutics Inc
28/11/202313:00GlobeNewswire Inc.Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian CancerNASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Your Recent History

LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
AAU
Ariana Resources
LSE
LLOY
Lloyds Banking
LSE
BT.A
Bt
LSE
INSG
Insig Ai
LSE
TERN
Tern
LSE
HUM
Hummingbird Resources
LSE
MIN
Minoan
LSE
APTA
Aptamer
LSE
BIRD
Blackbird
LSE
ALBA
Alba Mineral Resources
LSE
THUS
Thus
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved